Key Highlights

  • Rising Dragon Acquisition (NASDAQ:RDAC) climbed 101.37% to USD 10.27 after a mutual Merger termination with HZJL Cayman Limited.
  • Rockwell Medical (NASDAQ:RMTI) rose 11.04% to USD 7.67 after agreeing to acquire Vantive's hemodialysis concentrates business, with closing expected in mid-2027.
  • SmartKem (NASDAQ:SMTK) fell 16.03% to USD 0.2950 as a Form S-1 and the Ferrox merger stay in focus.
  • SHF Holdings (NASDAQ:SHFS) slipped 17.10% to USD 0.0383 amid non-binding Opifex Media deal talks.
  • Callan JMB (NASDAQ:CJMB) gained 12.42% to USD 0.3946 after a QuickStrip production line announcement.

Rising Dragon Acquisition (NASDAQ:RDAC) (up USD 5.17, 101.37%): A Failed Deal and Shares That Double

In pre-market trading on November 3, 2026, Rising Dragon Acquisition (NASDAQ:RDAC) rose 101.37% to USD 10.27. A press release dated November 3, 2026 announced a mutual termination of the merger agreement with HZJL Cayman Limited, effective October 30, 2026, and neither side owes a termination fee.

The Cayman Islands blank check company said it will continue pursuing an initial Business combination with another suitable target. It did not explain why the shares more than doubled after news that a deal fell through, and it did not disclose how much cash remains in trust. A move of this size on a small share base can reverse sharply.

Rockwell Medical (NASDAQ:RMTI) (up USD 0.7626, 11.04%): A Dialysis Purchase With Terms Kept Private

Rockwell Medical (NASDAQ:RMTI) rose 11.04% to USD 7.67 in pre-market trading on November 3, 2026. The company revealed a definitive agreement to acquire Vantive's hemodialysis concentrates, monitors and water treatment systems, along with related consumables and technical services. Vantive's dialyzer portfolio, including the Theranova dialyzer, is excluded, and closing is expected in mid-2027, subject to regulatory approvals.

The release content reviewed did not disclose price or financing terms. Cash, equivalents and investments were USD 24.8 million at June 30, 2026. Any Equity issuance to fund the purchase could dilute shareholders.

SmartKem (NASDAQ:SMTK) (down USD 0.0563, 16.03%): A Penny Stock Retreats After a Monday Spike

SmartKem (NASDAQ:SMTK) dropped 16.03% to USD 0.2950 in pre-market trading on November 3, 2026. The move is measured against a November 2 close of roughly USD 0.3513 (calculated). The company filed a Form S-1 dated November 2, 2026, and its terms were not identified.

The all-stock merger with Ferrox Critical Minerals, announced August 3, 2026, values Ferrox at about USD 125 million and must close by March 31, 2027. The S-3 filed in September carried an auditor Going Concern note. As a penny stock, SmartKem brings high volatility, thin Liquidity and dilution risk.

SHF Holdings (NASDAQ:SHFS) (down USD 0.0079, 17.10%): Falling Under USD 0.04 Amid Deal Talks

In pre-market trading on November 3, 2026, SHF Holdings (NASDAQ:SHFS) fell 17.10% to USD 0.0383. No company announcement dated November 2 or November 3 was identified. The stock has dropped about 66.9% from its USD 0.1158 close on October 27 (calculated).

An October 26, 2026 announcement described a non-binding term sheet with Opifex Media, under which Opifex holders would own 85% of the combined company before closing financing and an incentive reserve. The company said it cannot assure that a definitive agreement will be signed. Preferred conversions produced 23,914,988 new common shares, and Nasdaq pushed the bid price compliance deadline to April 19, 2027. This penny stock carries dilution risk.

Callan JMB (NASDAQ:CJMB) (up USD 0.0436, 12.42%): A Penny Stock Responds to a Production Line

Callan JMB (NASDAQ:CJMB) gained 12.42% to USD 0.3946 in pre-market trading on November 3, 2026. A company release dated November 2, 2026 reported that a QuickStrip oral thin-film production line from Rapid Dose Therapeutics had arrived at its Texas facility. Management said the platform could generate up to USD 15 million in Revenue in its first 18 months, conditional on successful qualification of the equipment.

The release gave no installation timeline, equipment cost or margins. The company said neither project requires it to raise additional capital, yet no cash balances or financing terms were provided, and the shares can be volatile and thinly traded.

The Takeaway

These five stories show how differently a deal headline can play out in the market. A terminated merger doubled one SPAC, a signed acquisition lifted a dialysis supplier, and three penny stocks are moving on filings, term sheets and projections that remain unconfirmed. Keep an eye on the Form 8-K from Rising Dragon Acquisition, the purchase price and financing disclosure from Rockwell Medical, the S-1 details at SmartKem, any definitive agreement at SHF Holdings, and qualification updates at Callan JMB.